MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • 2023 International Congress

    Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This exploratory trial aims to compare treatment outcomes of adding one daily dose of opicapone (OPC) 50 mg versus an additional dose of levodopa…
  • 2023 International Congress

    Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study

    P. Lorenzo-Barreto, I. Pareés, P. Pérez-Torre, S. Fanjul, JL. López-Sendón, F. Pérez-Trapote, A. Sáez-Marín, E. Stiauren-Fernández, á. Patiño-Patón, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

    Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…
  • 2023 International Congress

    Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.

    M. öthman, P. Odin, F. Bergquist, A. Johansson, R. Constantinescu, M. Scharfenort, H. Widner, D. Nyholm (Uppsala, Sweden)

    Objective: To investigate efficacy, tolerability, and safety of levodopa-entacapone-carbidopa intestinal gel (LECIG) in Parkinson’s disease. Background: LECIG was introduced in 2019. The approval was based…
  • 2023 International Congress

    Opicapone’s Effects on Progression Scales in Relation to the 9-Symptom Wearing-off Questionnaire: the OPTIPARK Study

    D. Martins, A. Lees, H. Reichmann, J-F. Rocha (Coronado, Portugal)

    Objective: This study aims to evaluate changes in Parkinson’s disease (PD) progression scales in patients with PD and motor fluctuations (MF) treated with once-daily opicapone…
  • 2022 International Congress

    Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson’s Disease

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This study aims to explore the potential of once-daily opicapone (OPC) 50 mg to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi)…
  • 2022 International Congress

    OCEAN Study in Parkinson’s Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone

    K. Chaudhuri, P. Odin, J. Ferreira, A. Antonini, O. Rascol, M. Kurtis, A. Storch, K. Bannister, R. Costa, D. Magalhães, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: This study aims to evaluate if treatment with opicapone (OPC) 50 mg once-daily can improve motor fluctuation (MF)-related pain in patients with Parkinson’s disease…
  • 2022 International Congress

    The REONPARK (REgistry of the use of COMT-inhibitors in the maNagement of patients with PARKinson’s disease in Spain who present early motor fluctuations) study: rationale and design of a national, multicentre and prospective study

    L. Lopez-Manzanares, E. Casas-Peña, I. Muro-Garcia, I. Caballero, F. Almeida, I. Tegel, P. Sarasa (Madrid, Spain)

    Objective: To describe the real-world use of catechol-O-methyltransferase (COMT) inhibitors add on to levodopa/dopa decarboxylase inhibitor (DDCI) in patients with Parkinson’s disease (PD) suffering from…
  • 2022 International Congress

    Early Morning Dystonia in Parkinson’s Patients Receiving Opicapone versus Entacapone: a Post-Hoc Analysis of BIPARK-I

    F. Stocchi, J. Ferreira, W. Poewe, O. Rascol, A. Antonini, J-F. Rocha (Rome, Italy)

    Objective: This study evaluated the effect of once-daily opicapone (OPC) 50 mg versus entacapone (ENT) on Early Morning Dystonia (EMD) in Parkinson’s disease patients with…
  • 2022 International Congress

    Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson’s Patients with Motor Fluctuations

    G. Castilla-Fernández, M. Fonseca, J. Ferreira, J-F. Rocha (Coronado, Portugal)

    Objective: This study compared the effects of catechol-O-methyl transferase (COMT) inhibitors and monoamine oxidase‑B (MAO-B) inhibitors on mean change from baseline to end-of-study in OFF-time…
  • 2022 International Congress

    OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?

    F. Colucci, V. Rispoli, V. Tugnoli, M. Pugliatti, G. Tecilla, M. Sensi (Ferrara, Italy)

    Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley